Amgen Acquires Horizon Therapeutics in Largest Healthcare Deal of 2022
Amgen Inc. announced on December 12 an agreement to acquire Horizon Therapeutics plc in the largest healthcare transaction of the year. Amgen will pay $116.50 for each Horizon share, totaling approximately $27.8 billion. Horizon was advised by Morgan Stanley and JPMorgan Chase & Co. Its legal advisers are Cooley LLP and Matheson LLP. Amgen’s lead financial adviser is PJT Partners and its financial adviser is Citigroup Inc. Its legal advisers are Sullivan Cromwell LLP and William Fry LLP. Horizon Therapeutics is an Irish biopharmaceutical company focused on developing medicines to treat rare autoimmune and severe inflammatory diseases. The company’s products are sold mostly... Read More »
Full-Life Technologies Purchases Focus-X Therapeutics for $245 Million
Full-Life Technologies announced on November 28 that it is acquiring Focus-X Therapeutics for $245 million. Founded in 2020, Focus-X created a proprietary engineering platform to develop peptide radioligands that precisely deliver alpha or beta emitters to break down cancer cell DNA. The company is based in Watchung, New Jersey. Shanghai-based Full-Life Technologies Limited is a fully integrated global radiotherapeutics company with operations in Europe and China. It was founded in 2021. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, and a peptide-focused discovery platform leveraging its radio technology manufacturing and logistics... Read More »
Boston Scientific Acquires Apollo Endosurgery
Boston Scientific Corp., a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, announced on November 29 it acquired Apollo Endosurgery in a $615 million deal. Under terms of the deal, Boston Scientific will pay $10 per share to acquire Apollo Endosurgery. Boston Scientific expects to complete the deal in the first half of 2023 and the company expects the acquisition to be accretive to its earnings per share after 2023. Apollo Endosurgery is known for manufacturing medical devices used during endoluminal surgery procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from... Read More »
AstraZeneca Acquires Neogene Therapeutics for up to $320 Million
AstraZeneca has acquired Neogene Therapeutics in a transaction valued at up to $320 million. Consideration will include an initial payment of $200 million upon closing, and a further amount of up to $120 million in contingent, milestones-based and non-contingent consideration. The transaction is expected to close in the first quarter of 2023. Upon completion of the transaction, Neogene Therapeutics will operate as a wholly owned subsidiary, with operations in Amsterdam, The Netherlands, and Santa Monica, California. Neogene Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and manufacturing transformative TCR therapies targeting neoantigens in solid... Read More »
Graybug Vision, CalciMedica Announce Merger
Graybug Vision, Inc. and CalciMedica Inc. have announced a merger agreement. Following the merger, the combined company will be headquartered in La Jolla, California. Rachel Leheny, Ph.D., will serve as CEO of the combined company. Graybug equity holders are expected to collectively own approximately 29% of the combined company, and pre-merger CalciMedica equity holders are expected to collectively own approximately 71% of the combined company. With approximately $35 million in cash and cash equivalents anticipated from the combined company, including a private placement financing expected to occur immediately prior to the merger closing, the combined company is expected to have a... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
